Q2 2026 Sight Sciences Inc Earnings Call Transcript
Key Points
- Sight Sciences Inc (SGHT) delivered a strong second quarter with total revenue growing 20% year-over-year, its highest growth rate since 2023 and the second consecutive quarter of double-digit growth.
- Interventional dry eye achieved record revenue of $2.7 million, nearly doubling from the first quarter, driven by a significant increase in ordering accounts (from 96 to 176) and higher average utilization.
- Interventional glaucoma revenue grew 8% year-over-year to $20.7 million, with ordering accounts reaching an all-time high and utilization returning to its highest level since Q4 2024.
- The company raised its full-year 2026 revenue guidance to $88 million to $92 million and lowered its adjusted operating expense guidance to $92 million to $94 million, reflecting improved operational efficiency.
- Sight Sciences Inc (SGHT) secured a major market access win with Aetna, adding approximately 25 million covered lives for its Omni and Scion procedures, and expanded TierCare patient lives with appropriate reimbursement to 14.5 million.
- The company's net loss improved significantly to $4.4 million, a 63% improvement year-over-year, and cash usage (excluding one-time items) decreased by 81% to $1.4 million, positioning it to achieve cash flow breakeven without raising additional equity.
- The company's interventional glaucoma growth is expected to moderate to mid-single-digits in Q3 2026, reflecting tougher prior-year comparisons and historically lower procedural trends in the third quarter.
- The company's gross margin was positively impacted by a one-time $1.4 million tariff refund; excluding this benefit, interventional glaucoma gross margin was 86%, in line with the prior year, and interventional dry eye gross margin was 80%.
- The company has not yet received any cash from the $55 million Alcon patent litigation judgment, as Alcon has filed an appeal, and the company continues to progress through the remaining legal and appellate processes.
- The company's interventional dry eye revenue guidance for Q3 2026 is approximately $3 million, which, while showing sequential growth, represents a significant slowdown from the near-doubling seen in Q2.
- The company's updated guidance does not assume incremental market access wins in the back half of 2026, meaning that any additional payer coverage decisions would be upside but are not guaranteed.
- The company will continue to make investments in SG&A, particularly in TierCare commercial build-out and market access, which will lead to an uptick in operating expenses in the back half of the year.
Good day, and thank you for standing by. Welcome to the CiteSciences Second Quarter 2026 Earnings Results Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question, please press *11 on your phone.
And you will hear an automated message advising your hand is raised. To withdraw your question, please press *11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to Tripp Taylor with Investor Relations. Please go ahead.
Thank you for participating in today's call. Presenting today are SiteSciences Co-Founder and Chief Executive Officer, Paul Badawi and Chief Financial Officer, Jim Rodberg. Also in attendance is SiteSciences Chief Operating Officer, Ali Bauerlein. Earlier today, SiteSciences released financial results for the second quarter ended June 30, 2026 and raised its revenue guidance and lowered its adjusted operating expense guidance
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
